Abstract
Children with problematic asthma represent about 0.5% of the population but consume a disproportionate amount of healthcare staff time and resources. The most important step in managing children with problematic asthma is differentiating those with genuine severe, therapy resistant disease from those who have difficult to treat asthma for a variety of other remediable factors. The most common causes of poor symptom control are poor adherence to therapy, ongoing exposure to sensitized allergens or co-morbid psychosocial problems. In up to half of the children with problematic asthma, addressing these simple factors can avoid further escalation of treatment or more invasive investigation. All asthmatic children with poor control despite treatment with ≥ 800μg of inhaled budesonide (or equivalent) should be referred to a paediatric respiratory specialist for evaluation. Management of children with problematic asthma, and particularly those with genuine severe therapy resistant disease, requires a stepwise multidisciplinary approach.
Keywords: Asthma, problematic, severe, difficult, adherence, steroid-sparing
Current Pediatric Reviews
Title: Severe Asthma: Why do Some Children Not Respond to Treatment?
Volume: 6 Issue: 2
Author(s): Ruth O'Reilly and Sejal Saglani
Affiliation:
Keywords: Asthma, problematic, severe, difficult, adherence, steroid-sparing
Abstract: Children with problematic asthma represent about 0.5% of the population but consume a disproportionate amount of healthcare staff time and resources. The most important step in managing children with problematic asthma is differentiating those with genuine severe, therapy resistant disease from those who have difficult to treat asthma for a variety of other remediable factors. The most common causes of poor symptom control are poor adherence to therapy, ongoing exposure to sensitized allergens or co-morbid psychosocial problems. In up to half of the children with problematic asthma, addressing these simple factors can avoid further escalation of treatment or more invasive investigation. All asthmatic children with poor control despite treatment with ≥ 800μg of inhaled budesonide (or equivalent) should be referred to a paediatric respiratory specialist for evaluation. Management of children with problematic asthma, and particularly those with genuine severe therapy resistant disease, requires a stepwise multidisciplinary approach.
Export Options
About this article
Cite this article as:
O'Reilly Ruth and Saglani Sejal, Severe Asthma: Why do Some Children Not Respond to Treatment?, Current Pediatric Reviews 2010; 6 (2) . https://dx.doi.org/10.2174/157339610791561150
DOI https://dx.doi.org/10.2174/157339610791561150 |
Print ISSN 1573-3963 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6336 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Prosthetic Valve Endocarditis: Diagnostic Approach and Treatment Options
Cardiovascular & Hematological Disorders-Drug Targets Recent Patents on Drugs Addressing Neurodegenerative Diseases
Recent Patents on Biomarkers Targeting Cytosolic Phospholipase A2α for Novel Anti-Inflammatory Agents
Current Medicinal Chemistry Molecular, Cellular and Clinical Aspects of Intracerebral Hemorrhage: Are the Enemies Within?
Current Neuropharmacology Enhanced Hippocampal Neurogenesis in APP/Ps1 Mouse Model of Alzheimer's Disease After Implantation of VEGF-loaded PLGA Nanospheres
Current Alzheimer Research Ligands and Therapeutic Perspectives of Adenosine A2A Receptors
Current Pharmaceutical Design Molecular Dynamics of Protein Kinase-Inhibitor Complexes: A Valid Structural Information
Current Pharmaceutical Design A Series of 2,4(1H,3H)-Quinazolinedione Derivatives: Synthesis and Biological Evaluation as Potential Anticancer Agents
Letters in Drug Design & Discovery Anticancer Effects of the Organosilicon Multidrug Resistance Modulator SILA 421
Anti-Cancer Agents in Medicinal Chemistry Lysophospholipids: Their Generation, Physiological Role and Detection. Are They Important Disease Markers?
Mini-Reviews in Medicinal Chemistry Activated Protein C and Acute Kidney Injury: Selective Targeting of PAR-1
Current Drug Targets The Cardiovascular and Cardiac Actions of Ecstasy and its Metabolites
Current Pharmaceutical Biotechnology New Trends in Medicinal Chemistry Approaches to Antiobesity Therapy
Current Topics in Medicinal Chemistry Nutraceuticals, Nutritional Therapy, Phytonutrients, and Phytotherapy for Improvement of Human Health: A Perspective on Plant Biotechnology Application
Recent Patents on Biotechnology Novel Aglycones of Steroidal Glycoalkaloids as Potent Tyrosine Kinase Inhibitors: Role in VEGF and EGF Receptors Targeted Angiogenesis
Letters in Drug Design & Discovery Cardiovascular Effects of Phosphodiesterase 5 Inhibitors
Current Pharmaceutical Design Nebivolol: More Than a Highly Selective Beta Blocker
Recent Patents on Cardiovascular Drug Discovery Do Adult Stem Cells Ameliorate the Damaged Myocardium? Human Cord Blood as a Potential Source of Stem Cells
Current Vascular Pharmacology Computational Approaches on Angiotensin Receptors and Their Ligands: Recent Developments and Results
Current Medicinal Chemistry Nanoparticles for Tumor Targeted Therapies and Their Pharmacokinetics
Current Drug Metabolism